Beryllium-induced lung disease exhibits expression profiles similar to sarcoidosis

European Respiratory Journal

Volumn 47, Issue 6, 2016, Pages 1797-1808

  Li, Li ^a,b   Silveira, Lori J ^a   Hamzeh, Nabeel ^a,b   Gillespie, May ^a   Mroz, Peggy M ^a   Mayer, Annyce S ^a,b,c   Fingerlin, Tasha E ^a   Maier, Lisa A ^a,b,c  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BERYLLIUM SULFATE; CORTICOSTEROID; CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; JANUS KINASE; JANUS KINASE 2 INHIBITOR; STAT PROTEIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; BERYLLIUM; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; BERYLLIOSIS; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOGENESIS; LUNG PARENCHYMA; MALE; MICROARRAY ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SARCOIDOSIS; SIGNAL TRANSDUCTION; CHEMICALLY INDUCED; CHRONIC DISEASE; CYTOLOGY; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; LUNG DISEASE; MIDDLE AGED; MONONUCLEAR CELL; OCCUPATIONAL EXPOSURE; PATHOPHYSIOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BERYLLIOSIS; BERYLLIUM; CHRONIC DISEASE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LUNG DISEASES; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; SARCOIDOSIS; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84973512780     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01469-2015     Document Type: Article

References (47)

1. Henneberger PK, Cumro D, Deubner DD, et al. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health 2001; 74: 167-176.
2. Newman L, Mroz MM, Balkissoon R, et al. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am J Respir Crit Care Med 2005; 171: 54-60.
3. Saltini C, Richeldi L, Losi M, et al. Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur Respir J 2001; 18: 677-684.
4. Infante P, Newman L. Beryllium exposure and chronic beryllium disease. Lancet 2004; 363: 415-416.
5. Henneberger P, Miller W, Doney B, et al. Industries in the United States with airborne beryllium exposure and estimates of the number of current workers potentially exposed. J Occup Environ Hyg 2004; 1: 648-659.
6. Maier L, Mroz M, Rossman M, et al. Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease. Respir Med 2012; 106: 1810-1813.
7. + T cells in patients with chronic beryllium disease. J Clin Invest 2002; 110: 1473-1482.
8. Maier L, Sawyer R, Tinkle S, et al. IL-4 fails to regulate in vitro beryllium-induced cytokines in berylliosis. Eur Respir J 2001; 17: 403-415.
9. + T cells in blood determines proliferative response. J Clin Invest 2005; 115: 2886-2893.
10. Sawyer R, Doherty D, Schumacher B, et al. Beryllium-stimulated in vitro migration of peripheral blood lymphocytes. Toxicology 1999; 138: 155-163.
11. Chaudhary A, Sauer N, Gupta G. Beryllium-specific immune response in primary cells from healthy individuals. Toxicology 2004; 201: 9-19.
12. Lehnert N, Gary R, Marrone B, et al. Inhibition of normal human lung fibroblast growth by beryllium. Toxicology 2001; 160: 119-127.
13. Gaede K, Mamat U, Schlaak M, et al. Analysis of differentially regulated mRNAs in peripheral blood monocytes of berylliosis patients after figure stimulation. J Mol Med 2000; 78: 293-299.
14. Hong-Geller E, Pardington PE, Cary RB, et al. Chemokine regulation in response to beryllium exposure in human peripheral blood mononuclear and dendritic cells. Toxicology 2006; 218: 216-228.
15. Zhou T, Zhang W, Sweiss N, et al. Peripheral blood gene expression as a novel genomic biomarker in complicated sarcoidosis. PLoS One 2012; 7: e44818.
16. Su R, Li M, Bhakta N, et al. Longitudinal analysis of sarcoidosis blood transcriptomic signatures and disease outcomes. Eur Respir J 2014; 44: 985-993.
17. Koth L, Solberg O, Peng J, et al. Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. Am J Respir Crit Care Med 2011; 184: 1153-1163.
18. Crouser E, Culver D, Knox K, et al. Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis. Am J Respir Crit Care Med 2009; 179: 929-938.
19. + subset in the lung of chronic beryllium disease. PLoS One 2015; 10: e0117276.
20. Forreryd A, Johansson H, Albrekt AS, et al. Evaluation of high throughput gene expression platforms using a genomic biomarker signature for prediction of skin sensitization. BMC Genomics 2014; 15: 379.
21. Li L, Zheng H, Gillespie M, et al. p38 mitogen-activated protein kinase in beryllium-induced dendritic cell activation. Human Immunol 2014; 75: 1155-1162.
22. Irizarry R, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
23. Li C, Wong W. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol 2001; 2: 0032.1-0032.11.
24. Smyth GK Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: 3.
25. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102: 15545-15550.
26. Mootha V, Lindgren C, Eriksson K, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34: 267-273.
27. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
28. Malemud C, Miller A. Pro-inflammatory cytokine-induced SAPK/MAPK and JAK/STAT in rheumatoid arthritis and the new anti-depression drugs. Expert Opin Ther Targets 2008; 12: 171-183.
29. Walker JG, Ahern MJ, Coleman M, et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis 2006; 65: 149-156.
30. Ivashkiv L. Type I interferon modulation of cellular responses to cytokines and infectious pathogens: potential role in SLE pathogenesis. Autoimmunity 2003; 36: 473-479.
31. Glas J. Evidence for STAT4 as a common autoimmune gene: rs7574865 is associated with colonic Crohn's disease and early disease onset. PLoS One 5: e10373.
32. Maertzdorf J. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci U S A 109: 7853-7858.
33. Zhou T, et al. Peripheral blood gene expression as a novel genomic biomarker in complicated sarcoidosis. PLoS One 7: e44818.
34. Mesa R, Yasothan U, Kirkpatrick P. Ruxolitinib. Nat Rev Drug Discov 2012; 11: 103-104.
35. Vaddi K, Sarlis N, Gupta V. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. Expert Opin Pharmacother 2012; 13: 2397-2407.
36. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011; 29: 789-796.
37. Nagata K, Maruyama K, Uno K, et al. Simultaneous analysis of multiple cytokines in the vitreous of patients with sarcoid uveitis. Invest Ophthalmol Vis Sci 2012; 53: 3827-3833.
38. Ziegenhagen M, Muller-Quernheim J. The cytokine network in sarcoidosis and its clinical relevance. J Intern Med 2003; 253: 18-30.
39. Plessner H, Lin PL, Kohno T, et al. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 2007; 195: 1643-1650.
40. Lin P, Myers A, Smith L, et al. Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum 2010; 62: 340-350.
41. Maier L, Sawyer R, Bauer R, et al. High beryllium-stimulated TNF-α is associated with the -308 TNF-α promoter polymorphism and with clinical severity in chronic beryllium disease. Am J Respir Crit Care Med 2001; 164: 1192-1199.
42. Sato H, Silveira L, Fingerlin T, et al. TNF polymorphism and bronchoalveolar lavage cell TNF-alpha levels in chronic beryllium disease and beryllium sensitization. J Allergy Clin Immunol 2007; 119: 687-696.
43. + T cells in blood as a biomarker of disease progression. J Allergy Clin Immunol 2011; 128: 1100-1106.
44. Brierley M, Fish E. Stats: multifaceted regulators of transcription. J Interferon Cytokine Res 2005; 25: 733-744.
45. Rosenbaum J, Pasadhika S, Crouser E, et al. Hypothesis: sarcoidosis is a STAT1-mediated disease. Clin Immunol 2009; 132: 174-183.
46. Fuller C, Flynn J, Reinhart T. In situ study of abundant expression of proinflammatory chemokines and cytokines in pulmonary granulomas that develop in cynomolgus macaques experimentally infected with Mycobacterium tuberculosis. Infect Immun 2003; 71: 7023-7034.
47. Abba M, Lacunza E, Nunez M, et al. Rhomboid domain containing 2 (RHBDD2): a novel cancer-related gene over-expressed in breast cancer. Biochim Biophys Acta 2009; 1792: 988-997.